 | |
 | |
| Combination of | |
|---|---|
| Lopinavir | Protease inhibitor |
| Ritonavir | Protease inhibitor (pharmacokinetic booster) |
| Clinical data | |
| Trade names | Kaletra, Aluvia |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602015 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| NIAID ChemDB | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
Lopinavir/ritonavir (LPV/r), sold under the brand name Kaletra among others, is a fixed-dose combination antiretroviral medication for the treatment and prevention of HIV/AIDS.[4] It combines lopinavir with a low dose of ritonavir.[4] It is generally recommended for use with other antiretrovirals.[4] It may be used for prevention after a needlestick injury or other potential exposure.[4] It is taken by mouth as a tablet, capsule, or solution.[4]
Common side effects include diarrhea, vomiting, feeling tired, headaches, and muscle pains.[4] Severe side effects may include pancreatitis, liver problems, and high blood sugar.[4] It is commonly used in pregnancy and it appears to be safe.[4] Both medications are HIV protease inhibitors.[4] Ritonavir functions by slowing down the breakdown of lopinavir.[4]
Lopinavir/ritonavir as a combination medication was approved for use in the United States in 2000.[4] It is on the World Health Organization's List of Essential Medicines.[5]
- ^ "Kaletra Product information". Health Canada. 19 March 2019. Retrieved 18 March 2020.
- ^ Cite error: The named reference
Kaletra FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Kaletra EPARwas invoked but never defined (see the help page). - ^ a b c d e f g h i j k "Lopinavir and Ritonavir". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 28 November 2016.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.